bioXXmed AG

Equities

T5O

DE000A0KFRJ1

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 11:36:08 2024-04-26 am EDT			5-day change	1st Jan Change
0.488 ^EUR	+4.27%		+3.83%	+9.42%

2023	BioXXmed AG Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	BioXXmed AG Reports Earnings Results for the Full Year Ended December 31, 2022	CI

BioXXmed AG Reports Earnings Results for the Half Year Ended June 30, 2023

September 30, 2023 at 03:12 am EDT

bioXXmed AG reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 0.012411 million compared to EUR 0.00413 million a year ago. Net loss was EUR 0.31092 million compared to EUR 0.480053 million a year ago.

Latest news about bioXXmed AG

BioXXmed AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-30	CI
BioXXmed AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-06-27	CI
CytoTools AG Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-31	CI
CytoTools AG Reports Earnings Results for the Full Year Ended December 31, 2021	22-06-30	CI
CytoTools AG announced that it has received €4.382517 million in funding	22-05-18	CI
CytoTools AG Announces Board Retirements	21-09-29	CI
CytoTools Reports Progress of DermaPro(R) Phase III Study in Europe and Provides Operational Status Update	21-09-29	CI
Lordstown Motors says hedge fund may buy up to $400 million of its stock	21-07-26	RE
Lordstown Motors : says hedge fund may buy up to $400 mln of its stock	21-07-26	RE
Cytotools Ag Reports Earnings Results for the Full Year Ended December 31, 2020	21-06-30	CI
CytoTools AG's Licensing Partner Centaur Pharmaceuticals Inc. Receives Tentative Approval for Woxheal(R) in Kenya, Africa	21-06-21	CI
CytoTools : Joins Activoris Medizintechnik To Develop Inhalation Therapy	21-04-26	MT
CytoTools Signs Collaboration Agreement to Develop Inhalation Therapy for Viral Infections Such as COVID-19 and Influenza	21-04-26	CI
CytoTools AG and Centaur Pharmaceuticals Achieves A Good Start to the Marketing of Its Active Ingredient for the Treatment of Diabetic Foot Syndrome in India	21-02-22	CI
CyTotools Receives Confirmation of Efficacy of DPCOL Also Against Influenza Viruses	20-12-21	CI
CytoTools AG Receives the Preliminary Results of the Test Series with the Active Substance DPOCL	20-11-13	CI
CytoTools Starts Phase III Study of DermaPro in Europe	20-10-29	CI
CytoTools AG Appoints Marc Herwick to the Management Board of the Company	20-10-06	CI
CytoTools AG Secures Financing of the Phase III Study	20-10-06	CI
CytoTools Examines the Effectiveness of Its Patented Active Substance DPOCL in COVID-19 Infections	20-09-17	CI
CytoTools AG Partner Centaur Pharmaceuticals Pvt Ltd Starts Marketing the Active Substance DPOCL in India	20-09-03	CI
CytoTools AG announced that it has received €3.7 million in funding from PIH Pharma Industry Holding GmbH	20-08-25	CI
Cytotools Ag Reports the Treatment of the Last Patients in the Phase II Trial of Dermapro Carried by DermaTools Biotech GmbH	19-07-04	CI
CytoTools AG announced that it has received €3 million in funding	19-05-02	CI
CytoTools AG Reports on the Expected Successful Course of the Current Dosage Determination Trial of DermaPro in Phase II	19-03-07	CI

Chart bioXXmed AG

Duration

Period

More charts

Company Profile

bioXXmed AG, formerly CytoTools AG, is a Germany-based holding company that invests in biotechnological or medical technology companies with equity or borrowed capital. The Company holds interests in research and development (R&D) companies DermaTools Biotech GmbH, which is active in the field of dermatology and urology, and CytoPharma GmbH, which is engaged in product development for cardiovascular diseases, cancer and other indications. bioXXmed AG manages the patent portfolio and coordinates the licensing for its subsidiaries. The product pipeline of disease modifying therapies based on the mechanisms of cell growth and programmed cell death, comprising small molecules and biologics across a range of disease indications, includes DermaPro, the Company's lead product indicated for diabetic and venous foot ulcers in phase III of clinical trials, as well as Utisept, an urological medical device for flushing the bladder in urinary tract infections.

Sector

Biotechnology & Medical Research

Calendar

2024-06-23 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOXXMED AG	+9.42%	2.68M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research